Budget Impact Analysis of The Inclusion of Tofacitinib In The Public List of Reimbursement In The Treatment of Rheumatoid Arthritis After Inadequate Response To Methotrexate In Colombia
Abstract
Authors
J. Vargas-Valencia V.A. Prieto E. Jáuregui D. Fernandez-Avila M.R. Chalem-Choueka G. Vasquez